Results 1 to 10 of about 175,079 (189)

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma [PDF]

Journal of Hematology & Oncology
Background CD19-directed chimeric antigen receptor T-cell therapy (CD19-CAR) has yielded encouraging efficacy in CNS lymphomas (CNSL), but most patients ultimately experience progressive disease (PD). Risk factors, progression patterns as well as optimal
Leon D. Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, Jeremy S. Abramson, Jacob D. Soumerai, Maria Martinez-Lage, J. Erika Haydu, Ganesh M. Shankar, Chirayu Patel, Bryan D. Choi, Jeffrey A. Barnes, Areej El-Jawahri, Ephraim P. Hochberg, P. Connor Johnson, Wolfgang Wick, Marcela V. Maus, Yi-Bin Chen, Matthew J. Frigault, Jorg Dietrich   +18 more
doaj   +2 more sources

CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients

Biomarker Research
Cell- and antibody-based CD19-directed therapies have demonstrated great potential for treating B-cell non-Hodgkin lymphoma (B-NHL). However, all these approaches suffer from limited response rates and considerable toxicity.
Dominik Sonanini, Johannes Schwenck, Simone Blaess, Julia Schmitt, Andreas Maurer, Walter Ehrlichmann, Malte Ritter, Julia Skokowa, Manfred Kneilling, Gundram Jung, Falko Fend, Simon Krost, Christian M. Seitz, Peter Lang, Gerald Reischl, Rupert Handgretinger, Christian la Fougère, Bernd J. Pichler   +17 more
doaj   +4 more sources

A study on influence of different signal peptides on anti-tumor effect of chimeric antigen receptor (CAR) T cells [PDF]

Zhongguo aizheng zazhi, 2022
Background and purpose: Signal peptide (SP) is a short peptide chain at the N-terminal of precursor protein, which can regulate the folding and transfer of precursor protein and plays an important role in protein secretion.
LI Fan, ZHANG Qinxing, TONG Xiangwen, TIAN Gaohui, GU Lixing, XU Yao
doaj   +1 more source

CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19

Hematology/Oncology and Stem Cell Therapy, 2022
Chimeric antigen receptors (CARs) are synthetic engineered receptors with an antigen recognition domain derived from a high-specificity monoclonal antibody that can target surface molecules on tumor cells.
Yenny M. Vanegas, Razan Mohty, Martha E. Gadd, Yan Luo, Mahmoud Aljurf, Hong Qin, Mohamed A. Kharfan-Dabaja   +6 more
doaj   +1 more source

Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells in vitro and in vivo

Frontiers in Bioscience-Landmark, 2020
Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated clinical success in treatment of B-cell hematologic cancers. In this study, we compared human Transferrin epitope tagged CAR-T cells with non-tagged CAR-T cells for cytotoxicity, IFN ...
Michael Valentine, Le Li, Hua Zhou, Shirley Xu, Jinying Sun, Chengjing Liu, Hizkia Harto, Robert Berahovich, Vita Golubovskaya, Lijun Wu   +9 more
doaj   +1 more source

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

Pharmaceutics, 2020
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia
Gils Roex, Tom Feys, Yves Beguin, Tessa Kerre, Xavier Poiré, Philippe Lewalle, Peter Vandenberghe, Dominique Bron, Sébastien Anguille   +8 more
doaj   +1 more source

CAR T cell therapy

Immunological Medicine, 2021
Chimeric antigen receptor (CAR) is generated by fusing a cancer-specific antibody’s antigen recognition site with costimulatory molecules such as CD28 and CD3ζ. T cells transduced with CAR recognizes cancer-specific antigens and kill cancer cells.
Naoki Hosen
doaj   +1 more source

CD19-CAR Trials [PDF]

The Cancer Journal, 2014
CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs).
Carlos A, Ramos, Barbara, Savoldo, Gianpietro, Dotti   +2 more
openaire   +2 more sources

Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma: What is the Evidence?

Hematology/Oncology and Stem Cell Therapy, 2022
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T cell product, with a CD3Z activatory domain connected to 4-1BB costimulatory domain.
Mohamed A. Kharfan-Dabaja, Farah Yassine, Muhamad Alhaj Moustafa, Madiha Iqbal, Hemant Murthy   +4 more
doaj   +1 more source

CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes [PDF]

, 2013
B lymphocytes are an important cell population of the immune system. However, until recently it was not possible to transduce resting B lymphocytes with retro- or lentiviral vectors, making them unsusceptible for genetic manipulations by these vectors ...
A Pezzutto, A Yoder, AD Bucheit, B Anliker, C Demaison, C Frecha, C Frecha, C Frecha, CA Walshe, Christian J. Buchholz, CJ Buchholz, D Unutmaz, DA Tuveson, DD Sloan, Els Verhoeyen, Evren Alici, François-Loic Cosset, H Li, H Niiro, J Bruenke, J Uchida, JT Golay, K Akashi, K Itoh, L Ginaldi, M Fujimoto, M Kügler, M Peipp, M Serafini, M Zanetti, MD Mühlebach, Michael Schwenkert, MJ Polyak, MS Cragg, NE Harwood, Q Zhou, Q Zhou, Q Zhou, Qi Zhou, R Zufferey, RC Münch, RN Damle, RS Noyce, S Funke, S Kheirallah, S Kneissl, Sabrina Kneissl, T Nakamura, TF Tedder, X Li, Y Reiter, YD Korin   +51 more
core   +6 more sources